This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
DiMasi, J.A., Hansen, R.W. & Grabowski, H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003).
The Economics of TB Drug Development (The Global Alliance for TB Drug Development, October 2001).
Tollman, P. et al. A Revolution in R&D: How Genomics and Genetics are Transforming the Biopharmaceutical Industry (Boston Consulting Group, Boston, 2001).
Gilbert, J., Henske, P. & Singh, A. Rebuilding big pharma's business model. In Vivo 21, 1–4 (2003).
A Plan to Ensure Taxpayers' Interests are Protected: NIH Response to the Conference Report Request for a Plan to Ensure Taxpayers' Interests are Protected, July 2001 (http://www.nih.gov/news/070101wyden.htm - conclusion).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Show me the money. Nat Biotechnol 22, 663–664 (2004). https://doi.org/10.1038/nbt0604-663
Issue Date:
DOI: https://doi.org/10.1038/nbt0604-663
This article is cited by
-
The $802 million fallacy
Nature Biotechnology (2004)